1
|
Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Gruenewald I, Marra A, Schultheis A, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel W, Wiewrodt R, Hartmann W. Die prognostische Wertigkeit der Expression von PD1 und PDL1 im nicht kleinzelligen Lugenkarzinom. Pneumologie 2016. [DOI: 10.1055/s-0036-1571966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
2
|
Sievers E, Trautmann M, Kindler D, Huss S, Gruenewald I, Dirksen U, Renner M, Mechtersheimer G, Pedeutour F, Åman P, Nishio J, Schildhaus HU, Kirfel J, Schirmacher P, Wardelmann E, Buettner R, Hartmann W. SRC inhibition represents a potential therapeutic strategy in liposarcoma. Int J Cancer 2015; 137:2578-88. [PMID: 26084847 DOI: 10.1002/ijc.29645] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 06/03/2015] [Indexed: 11/11/2022]
Abstract
Liposarcomas (LS) are the most common malignant mesenchymal tumors, with an overall long-term mortality rate of 60%. LS comprise three major subtypes, i.e., well-differentiated/dedifferentiated liposarcoma (WDLS/DDLS), myxoid/round cell liposarcoma (MLS) and pleomorphic liposarcoma (PLS). Aiming at the preclinical identification of novel therapeutic options, we here investigate the functional significance of SRC in primary human LS and in LS-derived cell lines. Immunohistochemical and Western blot analyses reveal relevant levels of activated p-(Tyr416)-SRC in LS of the different subtypes with particular activation in MLS and PLS. Dysregulation of the SRC modifiers CSK and PTP1B was excluded as major reason for the activation of the kinase. Consistent siRNA-mediated knockdown of SRC or inhibition by the SRC inhibitor Dasatinib led to decreased proliferation of LS cell lines of the different subtypes, with MLS cells reacting particularly sensitive in MTT assays. Flow cytometric analyses revealed that this effect was due to a significant decrease in mitotic activity and an induction of apoptosis. SRC inhibition by Dasatinib resulted in dephosphorylation of SRC itself, its interacting partners FAK and IGF-IR as well as its downstream target AKT. Consistent with a particular role of SRC in cell motility, Dasatinib reduced the migratory and invasive potential of MLS cells in Boyden chamber and Matrigel chamber assays. In summary, we provide evidence that SRC activation plays an important role in LS biology and therefore represents a potential therapeutic target, particularly in MLS and PLS.
Collapse
Affiliation(s)
- Elisabeth Sievers
- Department of Pathology, University Hospital Cologne, Cologne, Germany.,Department of Pathology, University Hospital Bonn, Bonn, Germany
| | - Marcel Trautmann
- Department of Pathology, University Hospital Cologne, Cologne, Germany.,Department of Pathology, University Hospital Muenster, Muenster, Germany
| | - Dagmar Kindler
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - Sebastian Huss
- Department of Pathology, University Hospital Muenster, Muenster, Germany
| | - Inga Gruenewald
- Department of Pathology, University Hospital Muenster, Muenster, Germany
| | - Uta Dirksen
- Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany
| | - Marcus Renner
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | | | - Florence Pedeutour
- Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice, France
| | - Pierre Åman
- Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - Jun Nishio
- Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | | | - Jutta Kirfel
- Department of Pathology, University Hospital Bonn, Bonn, Germany
| | - Peter Schirmacher
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Eva Wardelmann
- Department of Pathology, University Hospital Cologne, Cologne, Germany.,Department of Pathology, University Hospital Muenster, Muenster, Germany
| | - Reinhard Buettner
- Department of Pathology, University Hospital Cologne, Cologne, Germany
| | - Wolfgang Hartmann
- Department of Pathology, University Hospital Cologne, Cologne, Germany.,Department of Pathology, University Hospital Muenster, Muenster, Germany
| |
Collapse
|